Skip to main content

Table 1 Baseline characteristics and invasive hemodynamics by edema classification

From: Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study

Characteristic

ALI/ARDS

CHF

P

n

33

21

 

Age, yr

60 ± 3

59 ± 5

0.81

Female sex, n (percentage)

21 (64)

10 (48)

0.25

Weight (kg)

74.7 ± 4.9

91.7 ± 6.8

0.04

Race, n (percentage)

   

   Black

16 (48)

10 (48)

 

   Caucasian

16 (48)

11 (52)

0.67

   Hispanic, non-black

1 (4)

0 (0)

 

APACHE II score

20.7 ± 1.1

20.2 ± 1.2

0.77

Lung injury score

2.6 ± 0.1

2.6 ± 0.2

1.0

Creatinine, mg/dl

1.2 ± 0.1

2.2 ± 0.3

<0.01

Vasoactive druga use, n (percentage)

15 (45)

11 (52)

0.25

Mechanical ventilation, n (percentage)

24 (72)

11 (52)

0.13

RHDb, n (percentage)

16 (48)

15 (71)

0.10

LVDc, n (percentage)

4 (12)

20 (95)

<0.01

RAP, mmHg

5.9 ± 6.3

15.2 ± 5.7

<0.0001

PCWP, mmHg (n = 5 and 9)

6.8 ± 2.5

21.4 ± 5.5

<0.0001

  1. ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; APACHE II, Acute Physiology and Chronic Health Evaluation II severity of illness; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure. Where errors are shown, results are means ± SD.
  2. aVasoactive drugs include dobutamine, milrinone, norepinephrine, phenylephrine, vasopressin or dopamine; bechocardiographic evidence of right ventricular dilatation, dysfunction and/or pulmonary hypertension or pulmonary artery catheter readings of mean pulmonary artery pressure ≥ 20 mmHg;cechocardiographic evidence of left ventricular dysfunction.